Navigation Links
AASLD President's Choice Lecture: The National Strategy for the Control of Viral Hepatitis and Liver Cancer
Date:11/1/2010

BOSTON, Nov. 1, 2010 /PRNewswire/ -- Dr. Howard Koh, the 14th Assistant Secretary for Health for the U.S. Department of Health and Human Services (HHS), described the steps the U.S. administration is taking in response to the recent Institute of Medicine (IOM) report on viral hepatitis in his 2010 President's Choice Lecture at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases (AASLD). Dr. Koh formed and led a U.S. Department of Health and Human Services-wide team that will soon issue a hepatitis action plan that will leverage new funding opportunities and integrate activities throughout HHS to build true systems of care for high-risk individuals.

Additionally, the plan will be used to strengthen partnerships with federal, professional, and patient organizations in an effort to set and implement policies to guide public health and clinical practice. Other goals of the plan will be to harmonize screening guidelines, create new strategies for workforce development, and improve hepatitis B vaccination rates for adults at high risk. Dr. Koh stressed the need for collaboration in addressing the epidemic of hepatitis, including the need to work with state and local health leaders and create stronger links with professional societies such as AASLD. The report will address the need for prevention and building the capacity for reducing the number and incidence of viral hepatitis infections and improving the health of patients and economic consequences of viral hepatitis.

Dr. Koh also praised the recent Trust for America's Health report developed in collaboration with AASLD that translates the IOM report into language that may be used to affect appropriations to support research and health care delivery for liver disease and also to be used in future legislation to make the screening, early detection, and treatment of viral hepatitis a reality.

Viral hepatitis is the fourth leading infectious cause of death, but is virtually unknown to health care providers, the general public, at-risk populations, and policymakers. Individuals with viral hepatitis are at increased risk for liver cancer and chronic liver disease, yet an estimated 70 percent of persons with chronic viral hepatitis do not know that they are infected. In the absence of appropriate treatment, 15 to 40 percent of infected persons will develop liver cirrhosis; viral hepatitis is also the leading cause of liver transplantation in the U.S. In addition, liver cancer rates have tripled over the last several decades in contrast to other types of cancer. Surveillance data suggest that nearly 20,000 people are newly infected with HCV every year.

Recent developments in many health-related areas can potentially contribute to lower rates of chronic hepatitis virus in the U.S. and improve health outcomes for infected persons. The HHS action plan reflects upon feedback received from both experts and the community, and will help HHS improve its existing efforts to prevent viral hepatitis and related disease in the following three ways:

  • Establishing priorities for the specific actions that must be taken, assigning lead and partner agencies with responsibility for meeting these priorities
  • Helping HHS build prevention and care capacity and improving the efficiency of current efforts through improved coordination of viral hepatitis activities across HHS operating divisions
  • Serving as a guide for HHS to engage other governmental agencies and nongovernmental organizations in viral hepatitis prevention and care

  • This action plan is organized into the following six topic areas, which correspond to IOM recommendations:

  • Increasing community awareness and provider education
  • Strengthening surveillance for viral hepatitis
  • Preventing viral hepatitis associated with injection-drug use
  • Preventing viral hepatitis transmission through vaccination
  • Preventing health care associated viral hepatitis
  • Improving screening, care, and treatment for viral hepatitis

  • About the AASLD

    AASLD is the leading medical organization for advancing the science and practice of hepatology. Founded by physicians in 1950, AASLD's vision is to prevent and cure liver diseases. This year's Liver Meeting®, held in Boston, Massachusetts, October 29- November 2, will bring together more than 7,500 researchers from 55 countries.

    A pressroom will be available from October 30 at the annual meeting. For copies of abstracts and press releases, or to arrange for pre-conference research interviews contact Gregory Bologna at 703-299-9766. To pre-register, call Ann Haran at 703-299-9766.

    Press releases and all abstracts are available online at www.aasld.org. Media Contact: Gregory Bologna703-299-9766gbologna@aasld.orgPress Room: October 30 – November 2, 2010Hynes Convention Center, Room 208Telephone: 617-954-3106This release was issued through The Xpress Press News Service, merging e-mail and satellite distribution technologies to reach business analysts and media outlets worldwide. For more information, visit http://www.XpressPress.com.


    '/>"/>
    SOURCE American Association for the Study of Liver Diseases
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
    2. Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C
    3. Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
    4. Idenix Announces Data Presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
    5. Pharmasset to Webcast an Investor Event from the AASLD Meeting
    6. ANA598 Data Presented at AASLD Highlight Positive Clinical Profile of DAA Entering Phase IIb
    7. Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD
    8. Thrombosis Guidelines Emphasize Difficult Choices for Pregnant Women
    9. Online H1N1 Management: FairChoice Helps Schools Respond to Infectious Disease on Campus
    10. IncentOne Introduces Next Generation of Healthy Choice Award(TM) Incentive Solution to Drive Consumer and Provider Engagement
    11. Fresenius Medical Care, N.A. Has Selected VitalRemedyMDs VitalProteinRx(TM) As Its Bar of Choice for Protein Replacement in Dialysis Patients
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/20/2017)... DUBLIN , April 20, 2017 Research ... Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market and ... to their offering. ... market for drug delivery technologies will rise from USD 20 Billion ... Global Drug Delivery Technologies - Innovation Driven by Rapidly ...
    (Date:4/20/2017)... Research and Markets has announced the ... Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies ... ... was valued at US$ 7,167.6 Mn in 2015, and is ... a CAGR of 5.6% from 2016 to 2024. ...
    (Date:4/19/2017)... 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the ... Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... Chief Executive Officer of the Company is scheduled to present on ... Bear and the Chairman of the Board, Tony Holler ... ...
    Breaking Medicine Technology:
    (Date:4/28/2017)... ... April 28, 2017 , ... Accreditation Commission for ... Care Association of America (HCAOA). This agreement allows HCAOA members to receive special ... as discounts on Accreditation University (AU) educational resources that help prepare HCAOA members ...
    (Date:4/28/2017)... , ... April 28, 2017 , ... Horizon Blue Cross ... the company’s credit rating of “A” and its outlook as “stable.” At the same ... reserves, which have fallen in recent years, dip below “capital adequacy” thresholds required for ...
    (Date:4/28/2017)... , ... April 28, 2017 , ... ... Replace tubes . These lamps offer an instant energy-saving solution for F32T8 fluorescent ... rewire fixtures or disconnect ballasts. These 50,000 hour rated lamps utilize the existing ...
    (Date:4/28/2017)... ... April 28, 2017 , ... The Texas Cord Blood Bank (TCBB), a program ... delivery team at Women’s Hospital at Renaissance in Edinburg for their outstanding efforts in ... and decide to donate. , “Women’s Hospital at Renaissance has been a collection ...
    (Date:4/28/2017)... ... April 28, 2017 , ... Bill Howe started his sewer and drain ... After Tina Howe joined the team, the Bill Howe brand was born and they ... rates, and giving back to the San Diego community in which they worked, lived ...
    Breaking Medicine News(10 mins):